dr. matulonis on toxicities with parp inhibitors in ovarian cancer
Published 7 years ago • 388 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
1:54
dr. matulonis on toxicities with olaparib for patients with ovarian cancer
-
2:31
toxicities associated with parp inhibitors in ovarian cancer
-
1:44
dr. matulonis on the current treatment landscape in ovarian cancer
-
1:37
dr. matulonis discusses maintenance in ovarian cancer
-
2:20
dr. matulonis discusses niraparib/pembrolizumab combo in platinum-resistant ovarian cancer
-
1:11
dr. o'malley on toxicity profiles of parp inhibitors in ovarian cancer
-
0:58
dr. matulonis on individualized dosing of niraparib in ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
1:47
dr. matulonis on the nova trial of niraparib maintenance therapy in ovarian cancer
-
2:35
dr. monk on choosing between parp inhibitors in ovarian cancer
-
1:52
dr. konecny on response to parp inhibitors in ovarian cancer
-
2:22
dr. konecny on the value of parp inhibitors in ovarian cancer
-
6:25
combinations with parp inhibitors for ovarian cancer
-
2:23
dr. moore on unanswered questions with parp inhibitors in ovarian cancer
-
1:08
dr. essel on repeat use of parp inhibitors in ovarian cancer
-
0:59
dr. slamon on parp inhibitors in ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
0:45
dr. coffman on safety concerns with parp inhibitors in ovarian cancer
-
1:56
dr. birrer on parp inhibitors in ovarian cancer